VRTX · 10-Q · 2026Q3 · Full report

FX / Currency Impact

VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 23 · Surprise 22

Vertex attributed part of its 16% third-quarter 2026 and 13% first-nine-months 2026 ex-U.S. revenue growth to favorable foreign-exchange impacts. Ex-U.S. revenue was $1,271.7 million in the quarter and $3,760.2 million in the first nine months, compared with $1,100.1 million and $3,323.3 million, respectively, in the corresponding 2025 periods. The filing also identifies net foreign-currency exchange gains and losses as a factor in other income or expense in the prior-year periods.

Key facts

• Vertex’s ex-U.S. revenues increased 16% in the third quarter and 13% in the first nine months compared with the corresponding prior-year periods, driven primarily by CF performance across geographies, ALYFTREK uptake, CASGEVY revenues and favorable foreign exchange impacts. source